墨西哥当局批准了LEQEMBI,这是一种新的阿尔茨海默氏病药物,为130多万患者带来了希望。 Mexican authorities approve LEQEMBI, a new Alzheimer's drug, offering hope to over 1.3 million sufferers.

墨西哥卫生当局已批准Eisai和Biogen生产的LEQEMBI,这是一种治疗早期阿尔茨海默氏病的药物。 Mexican health authorities have approved LEQEMBI, a drug for early Alzheimer's disease, produced by Eisai and Biogen. LEQEMBI是第一种针对大脑中的氨基类鲸目动物综合体来减缓认知下降的治疗方法。 LEQEMBI is the first treatment shown to slow cognitive decline by targeting amyloid-beta aggregates in the brain. 包括美国、日本和中国在内的几个国家已经批准了这一药物。 The drug is already approved in several countries including the US, Japan, and China. 由于约有130万墨西哥人受到阿尔茨海默氏病的影响,批准可以为病人带来新的希望。 With around 1.3 million Mexicans affected by Alzheimer's, the approval could provide new hope for patients. 药物的批准是基于成功的临床试验结果。 The drug's approval is based on successful clinical trial results.